Signal Transduction and Targeted Therapy (Mar 2024)

Contactin-associated protein-like 2 (CNTNAP2) mutations impair the essential α-secretase cleavages, leading to autism-like phenotypes

  • Qing Zhang,
  • Mengen Xing,
  • Zhengkai Bao,
  • Lu Xu,
  • Yang Bai,
  • Wanqi Chen,
  • Wenhao Pan,
  • Fang Cai,
  • Qunxian Wang,
  • Shipeng Guo,
  • Jing Zhang,
  • Zhe Wang,
  • Yili Wu,
  • Yun Zhang,
  • Jia-Da Li,
  • Weihong Song

DOI
https://doi.org/10.1038/s41392-024-01768-6
Journal volume & issue
Vol. 9, no. 1
pp. 1 – 12

Abstract

Read online

Abstract Mutations in the Contactin-associated protein-like 2 (CNTNAP2) gene are associated with autism spectrum disorder (ASD), and ectodomain shedding of the CNTNAP2 protein plays a role in its function. However, key enzymes involved in the C-terminal cleavage of CNTNAP2 remain largely unknown, and the effect of ASD-associated mutations on this process and its role in ASD pathogenesis remain elusive. In this report we showed that CNTNAP2 undergoes sequential cleavages by furin, ADAM10/17-dependent α-secretase and presenilin-dependent γ-secretase. We identified that the cleavage sites of ADAM10 and ADAM17 in CNTNAP2 locate at its C-terminal residue I79 and L96, and the main α-cleavage product C79 by ADAM10 is required for the subsequent γ-secretase cleavage to generate CNTNAP2 intracellular domain (CICD). ASD-associated CNTNAP2 mutations impair the α-cleavage to generate C79, and the inhibition leads to ASD-like repetitive and social behavior abnormalities in the Cntnap2 -I1254T knock-in mice. Finally, exogenous expression of C79 improves autism-like phenotypes in the Cntnap2 -I1254T knock-in and Cntnap2 −/− knockout mice. This data demonstrates that the α-secretase is essential for CNTNAP2 processing and its function. Our study indicates that inhibition of the cleavage by pathogenic mutations underlies ASD pathogenesis, and upregulation of its C-terminal fragments could have therapeutical potentials for ASD treatment.